BSW Wealth Partners Raises Stake in Pfizer, Inc. (PFE)
BSW Wealth Partners lifted its stake in shares of Pfizer, Inc. (NYSE:PFE) by 2.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,972 shares of the biopharmaceutical company’s stock after acquiring an additional 267 shares during the quarter. BSW Wealth Partners’ holdings in Pfizer were worth $444,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Asset Planning Services Ltd. increased its holdings in Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the period. Orrstown Financial Services Inc. increased its holdings in Pfizer by 23.0% during the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the period. Cable Hill Partners LLC increased its holdings in Pfizer by 6.0% during the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares during the period. Acropolis Investment Management LLC increased its holdings in Pfizer by 1.9% during the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares during the period. Finally, Kimelman & Baird LLC purchased a new position in Pfizer during the first quarter valued at approximately $203,000. 69.09% of the stock is currently owned by institutional investors and hedge funds.
In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares in the company, valued at approximately $2,436,346.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders sold a total of 426,291 shares of company stock valued at $14,475,911 in the last quarter. Insiders own 0.06% of the company’s stock.
Pfizer, Inc. (NYSE:PFE) traded down 0.71% on Wednesday, reaching $35.12. 8,786,073 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $33.38 and a 200-day moving average price of $33.48. The company has a market capitalization of $208.87 billion, a P/E ratio of 25.69 and a beta of 1.00. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.43.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.64 EPS. Equities research analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a $0.32 dividend. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. Pfizer’s dividend payout ratio is presently 94.12%.
Several equities analysts recently issued reports on PFE shares. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Jefferies Group LLC set a $35.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Thursday, August 24th. Berenberg Bank reissued a “hold” rating and set a $36.00 price objective (down from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. BidaskClub downgraded shares of Pfizer from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 13th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $37.72.
TRADEMARK VIOLATION WARNING: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/09/13/bsw-wealth-partners-raises-stake-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.